Primary Hyperoxaluria Clinical Trial
Official title:
A Phase III Double-blind, Randomised Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria
Verified date | October 2021 |
Source | OxThera |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will evaluate the efficacy and safety of OC5 in patients with PH.
Status | Completed |
Enrollment | 25 |
Est. completion date | April 15, 2021 |
Est. primary completion date | April 15, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years and older |
Eligibility | Inclusion Criteria: 1. Signed informed consent (as applicable for the age of the subject) 2. A diagnosis of PH (as determined by standard diagnostic methods). 3. eGFR < 90 ml/min/1.73 m2. The Schwartz formula will be used to estimate GFR for children (age below 18), and CKD-EPI formula will be used for adults (age 18 or above). 4. Plasma oxalate concentration =10 µmol/L in total plasma oxalate. 5. Male or female patients = 2 years of age. 6. Patients receiving vitamin B6 must be receiving a stable dose for at least 3 months prior to screening and must not change the dose during the study. Patients not receiving vitamin B6 at study entry must be willing to refrain from initiating pyridoxine during study participation. Exclusion Criteria: 1. Inability to swallow size 4 capsules. 2. Subjects that have undergone transplantation (solid organ or bone marrow). 3. Patients requiring dialysis or at immediate risk for kidney failure or expected to be in need of dialysis during the study period. 4. The existence of secondary hyperoxaluria, e.g. hyperoxaluria due to bariatric surgery or chronic gastrointestinal diseases such as cystic fibrosis, chronic inflammatory bowel disease and short-bowel syndrome. 5. Use of antibiotics to which O. formigenes is sensitive. (This includes current antibiotic use, or antibiotics use within 14 days of initiating study medication). 6. Current treatment with a separate ascorbic acid preparation. 7. Pregnant women (or women who are planning to become pregnant) or lactating women. 8. Women of childbearing potential who are not using adequate contraceptive precautions. Please see section 7.3 regarding requirements for contraception. 9. Presence of a medical condition that the Investigator considers likely to make the subject susceptible to adverse effect of study treatment or unable to follow study procedures or any condition that is likely to interfere with the study drug mechanism of action (such as abnormal GI function). 10. Participation in any interventional study of another investigational product, biologic, device, or other agent within 60 days prior to the first dose of OC5 or not willing to forego other forms of investigational treatment during this study. |
Country | Name | City | State |
---|---|---|---|
Belgium | Centre Hospitalier Universitaire de Liège | Liège | |
France | Hôpital Robert Debré | Paris | |
Germany | Kindernierenzentrum Bonn | Bonn | |
Spain | Hospital Vall d' Hebron | Barcelona | |
Tunisia | Hédi Chaker University Hospital | Sfax | |
Tunisia | Sahloul University Hospital | Sousse | |
Tunisia | Charles Nicolle University Hospital | Tunis | |
United Kingdom | Royal Free Hospital | London | |
United Kingdom | Nottingham Children's Hospital | Nottingham | |
United States | Vanderbilt University Hospital | Nashville | Tennessee |
Lead Sponsor | Collaborator |
---|---|
OxThera |
United States, Belgium, France, Germany, Spain, Tunisia, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline in Plasma Oxalate Concentration After 52 Weeks of Treatment | Change from baseline in total plasma oxalate concentration after 52 weeks of treatment in micromole/liter | 52 weeks | |
Secondary | Change From Baseline in Kidney Function | Evaluation based on eGFR calculation using the 2009 creatinine-based "Schwartz bedside" equation (for children below 18 years of age) (Schwartz et al., 2009) and 2009 creatinine-based CKD-EPI equation for adults (Levey et al., 2009). Subjects who turn 18 during the study period were continuously evaluated using the Schwartz equation, ie the equation used at baseline was kept throughout the study. | 52 weeks | |
Secondary | Frequency of Kidney Stone Events | Number of kidney stone events for each patient | Through week 48 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT00875823 -
International Registry for Primary Hyperoxaluria
|
N/A | |
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Completed |
NCT02340689 -
Primary Hyperoxaluria Mutation Genotyping/Phenotyping
|
||
Completed |
NCT00638703 -
Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients
|
Phase 2/Phase 3 | |
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Completed |
NCT03819647 -
Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria
|
Phase 2 | |
Recruiting |
NCT02026388 -
Rare Kidney Stone Consortium Biobank
|
||
Completed |
NCT02000219 -
Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on Dialysis
|
Phase 2 | |
Recruiting |
NCT05843851 -
Genetic Newborn Screening for Cystinosis and Primary Hyperoxaluria
|
N/A | |
Recruiting |
NCT00588562 -
Rare Kidney Stone Consortium Patient Registry
|
||
Completed |
NCT03391804 -
Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia
|
Phase 2 | |
Recruiting |
NCT05107830 -
Phenotyping of Primary Hyperoxaluria
|
||
Active, not recruiting |
NCT04152200 -
A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1
|
Phase 3 | |
Recruiting |
NCT05001269 -
Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function
|
Phase 2 | |
Completed |
NCT03392896 -
Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria
|
Phase 1 | |
Completed |
NCT02012985 -
Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary Hyperoxaluria
|
Phase 1/Phase 2 | |
Completed |
NCT01037231 -
Phase 2/3 Oxabact Study
|
Phase 2/Phase 3 | |
Completed |
NCT00589225 -
Primary Hyperoxaluria Mutation Genotyping
|
Phase 1 | |
Completed |
NCT02124395 -
Health-related Quality of Life in Rare Kidney Stone
|
||
Completed |
NCT03350451 -
An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1
|
Phase 2 |